[Successful low-dose TS-1 administration in an elderly colon cancer patient with liver metastasis].

An 85-year-old man, who had undergone right hemicolectomy and partial hepatectomy for caecum cancer with liver metastasis, was diagnosed with recurrent multiple liver metastasis 10 months after surgery. TS-1 administration at a dose of 80 mg/day induced grade 3 anorexia, and after complete recovery from the adverse reaction, it was converted to a low-dose TS-1 administration at 40 mg/day. This treatment reduced the diameter of the liver metastasis and was continued for ten months without any adverse reaction. Pharmacokinetic analysis in this patient on low-dose TS-1 showed that Cmax and AUC of 5-chloro-2,4-dihydroxypyridine (CDHP) were equivalent to the values reported in cancer patients with normal renal function receiving standard-dose administration. TS-1 therapy may provide a safe and effective alternative to chemotherapy for elderly patients with advanced colorectal carcinoma. Pharmacokinetic analysis could be useful for determining the ideal dose of TS-1.
AuthorsTadashi Ohnishi, Toshiyuki Kanoh, Yutaka Kimura, Takashi Iwazawa, Takeshi Tono, Yoshiaki Nakano, Koji Yano, Takushi Monden
JournalGan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 34 Issue 4 Pg. 623-5 (Apr 2007) ISSN: 0385-0684 [Print] Japan
PMID17431353 (Publication Type: Case Reports, English Abstract, Journal Article)
Chemical References
  • Antimetabolites, Antineoplastic
  • Drug Combinations
  • S 1 (combination)
  • Tegafur
  • Oxonic Acid
  • Adenocarcinoma (drug therapy, metabolism, secondary)
  • Aged, 80 and over
  • Antimetabolites, Antineoplastic (administration & dosage, pharmacokinetics)
  • Appendiceal Neoplasms (secondary, surgery)
  • Colonic Neoplasms (drug therapy, metabolism, pathology)
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Drug Combinations
  • Humans
  • Liver Neoplasms (secondary, surgery)
  • Male
  • Oxonic Acid (administration & dosage, pharmacokinetics)
  • Tegafur (administration & dosage, pharmacokinetics)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: